Abstract:
:Circulating homocysteine is a risk factor of cardiovascular and cerebrovascular events. Hyperhomocysteinemia may be an early indicator for vitamin B12 disorders because cobalamin is a cofactor in the remethylation process of homocysteine. Serum holotranscobalamin (holoTC II) becomes decreased before the development of metabolic dysfunction. In this study, we assessed circulating holoTC II to estimate the diagnosis of vitamin B12 deficiency in the first ischemic cerebrovascular attack. We also compared the efficacy of the measurement of plasma holoTC II with the other standard biochemical and hematological markers used to reach the diagnosis of cobalamin deficiency. Forty-five patients (age 71 years (range 35-90), 16 men/29 women) within the first ischemic cerebrovascular event were included in this prospective study. All the enrolled patients have been administered vitamin B12 1 mg intramuscular injection once a day for 10 days. At the baseline and on the tenth day of treatment, plasma levels of holoTC II and the proper biochemical and hematological markers in diagnosing cobalamin deficiency were measured. After admission, anemia and diminished serum vitamin B12 levels were determined to be only 20% (9/45) and 44% (20/45), respectively; 78% (35/45) of the patients had low serum holoTC II (<37 pmol/l). Serum homocysteine was higher in patients (49% of them) who had previously suffered a stroke. Thrombocytopenia, hypersegmentated neutrophils, and indirect hyperbilirubinemia were observed in 20% of the patients. Leukopenia and macrocytosis were not evident in any of them. In 18 of 27 patients (67%) that had low holoTC II levels after joining the study and who remained in the study until the end of cobalamin treatment, serum holoTC II levels returned to normal values. Cobalamin deficiency should be considered in patients with cerebrovascular diseases, even if anemia, elevated mean cell volume, depression of the serum cobalamin, or other classic hematological and/or biochemical abnormalities are lacking. Furthermore, measurement of serum holoTC II looks promising as a first-line of tests for diagnosing early vitamin B12 deficiency.
journal_name
Ann Hematoljournal_title
Annals of hematologyauthors
Serefhanoglu S,Aydogdu I,Kekilli E,Ilhan A,Kuku Idoi
10.1007/s00277-007-0406-3subject
Has Abstractpub_date
2008-05-01 00:00:00pages
391-5issue
5eissn
0939-5555issn
1432-0584journal_volume
87pub_type
临床试验,杂志文章abstract::Patients with primary refractory or relapsed acute myeloid leukemia (AML) who undergo intensive salvage chemotherapy carry a high risk of treatment failure due to infectious complications and early relapses. The study presented here assessed the effect of granulocyte colony-stimulating factor (G-CSF) on the duration o...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章
doi:10.1007/s002770050425
更新日期:1998-09-01 00:00:00
abstract::The development of thrombocytopenia following exposure to the platelet glycoprotein (GP) IIb/ IIIa receptor antagonist abciximab (c7E3 Fab, ReoPro) is associated with adverse clinical outcome and excessive bleeding. Pseudothrombocytopenia is an important differential diagnosis in sudden onset of thrombocytopenia in a ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002770050573
更新日期:2000-03-01 00:00:00
abstract::Assay of phosphotyrosine levels using flow cytometry has been used to identify patients with chronic myelogenous leukemia positive for the Bcr-Abl fusion gene. We hypothesized that clinical monitoring could identify treatment response through reductions in intragranulocyte phosphotyrosine. Initially, we studied cell l...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-008-0563-z
更新日期:2009-01-01 00:00:00
abstract::Blastic transformation of essential thrombocythemia (ET) preceded by chemotherapy is occasionally described in the literature. In ET as well as in other myeloproliferative disorders the leukemogenic effect of alkylating agents and (32)P is well established, and recent reports also indicate a certain leukemogenic effec...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002770050007
更新日期:2000-01-01 00:00:00
abstract::This retrospective single-center study compared thromboembolic and hemorrhagic complications, survival and causes of death in a cohort of 102 consecutive patients with myeloproliferative disorders (MPD). We included 17 patients with essential thrombocythemia (ET), 59 with polycythemia vera (PV), and 26 with osteomyelo...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002779900136
更新日期:2000-06-01 00:00:00
abstract::Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is used in patients with refractory chronic lymphocytic leukaemia (CLL). We report results in health care with alemtuzumab on consecutive, advanced-stage patients from a well-defined geographical region. Records from 1,301 patients (Stockholm-Cancer-Registry 1991...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-014-2105-1
更新日期:2014-10-01 00:00:00
abstract::Infections by multidrug-resistant (MDR) bacteria are a worrisome phenomenon in hematological patients. Data on the incidence of MDR colonization and related bloodstream infections (BSIs) in haematological patients are scarce. A multicentric prospective observational study was planned in 18 haematological institutions ...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究
doi:10.1007/s00277-018-3341-6
更新日期:2018-09-01 00:00:00
abstract::Patients older than 75 years old with multiple myeloma (MM) have shorter survival and are usually treated differently from what features in clinical trials. In this study, the authors characterized the Portuguese population of MM patients above 75 years old, treated between 2009 and 2016. We compared the outcomes obta...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1007/s00277-019-03640-y
更新日期:2019-07-01 00:00:00
abstract::The best treatment option for patients with relapsed or high-grade follicular lymphoma (FL) is unknown. In spite of major advances in the therapy for FL, disease-free survival remains short, and median time to progression is just over a year. Autologous stem cell transplantation in patients with relapsed FL is safe an...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-005-1058-9
更新日期:2005-08-01 00:00:00
abstract::We retrospectively analyzed very early chimerism before and ongoing neutrophil engraftment (days 7, 14, 21, 28) and investigated the influence of conditioning regimens and stem cell sources on donor-type chimerism in 59 Japanese patients who had received allogeneic hematopoietic stem cell transplantation. The percenta...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-008-0542-4
更新日期:2008-12-01 00:00:00
abstract::Immunoglobulin D (IgD) myeloma is a rare subtype that used to lead to a poor outcome. To investigate the current clinical features, cytogenetic changes and survival of patients with IgD myeloma under novel treatments, we analysed 47 patients with IgD myeloma, 31 men and 16 women, with a median age of 54.5 years. We fo...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-018-3582-4
更新日期:2019-04-01 00:00:00
abstract::High-dose chemotherapy (HDT) and stem cell transplantation is a newer treatment option widely applied in poor-risk germ cell tumor patients. Due to the increasing practical clinical experience and the availability of hematopoietic growth factors, this treatment approach has become a relatively safe procedure. Dependin...
journal_title:Annals of hematology
pub_type: 杂志文章,评审
doi:10.1007/s002770050386
更新日期:1998-05-01 00:00:00
abstract::Mesenchymal stem cells (MSCs) have emerged as a therapeutic approach in a range of medical fields, including regenerative medicine, cancer, autoimmune diseases, and inflammatory diseases, because of their unique properties of tissue repair and major histocompatibility complex-unmatched immunosuppression. Because both ...
journal_title:Annals of hematology
pub_type: 杂志文章,评审
doi:10.1007/s00277-013-1796-z
更新日期:2013-10-01 00:00:00
abstract::Patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy and do not achieve complete remission experience significantly shortened progression-free interval (PFS). Additionally, the majority of patients treated for relapsed disease demonstrate evidence of measurable disease. Eradication of minima...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章
doi:10.1007/s00277-016-2683-1
更新日期:2016-06-01 00:00:00
abstract::A 24-year-old woman with a large cell anaplastic CD 30-positive T-cell non-Hodgkin's lymphoma (NHL) developed downbeat nystagmus, anisocoria, and oscillopsia. Prior to overt cerebral invasion by NHL, she had a thiamine deficiency with very low thiamine concentrations in the CSF, probably caused by protracted vomiting ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002770050484
更新日期:1999-02-01 00:00:00
abstract::Relapse remains one of the major obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) even after allogeneic hematopoietic stem cell transplantation. The persistence of leukemia-propagating cells (LPCs) may lead to the recurrence of Ph+ALL. Using a xenograft assay, LPCs enrichment in the ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-018-3253-5
更新日期:2018-05-01 00:00:00
abstract::The present meta-analysis was undertaken to (1) assess erythroid response rates in myelodysplastic syndromes (MDS) patients treated with epoetin alfa as a monotherapy, (2) gain further insights into predictors of response rates, and (3) compare the erythroid response rates observed with epoetin alfa and darbepoetin al...
journal_title:Annals of hematology
pub_type: 杂志文章,meta分析,评审
doi:10.1007/s00277-008-0450-7
更新日期:2008-07-01 00:00:00
abstract::Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by overproduction of red blood cells. We have performed a comprehensive characterization of blood immune cells for expression of naïve and memory receptors as well as β2m-associated and β2m-free MHC class I heavy chains, also known as closed and ope...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-018-3332-7
更新日期:2018-09-01 00:00:00
abstract::A 57-year-old man with acute myeloid leukemia (AML) French-American-British (FAB) 4 developed disseminated invasive cerebral and pulmonary aspergillosis during postinduction aplasia. According to international consensus, infection was categorized as probable (two host factors: deep neutropenia for >10 days and refract...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-003-0792-0
更新日期:2004-06-01 00:00:00
abstract::Recombinant human granulocyte colony-stimulating factor (rhG-CSF) and erythropoietin (rhE-PO) were used to treat ten patients with myelodysplastic syndromes (MDS). None of the patients showed a favorable response in erythrocyte and platelet counts following 10 weeks' treatment, although favorable responses in neutroph...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/BF01834360
更新日期:1994-04-01 00:00:00
abstract::Second-generation azoles may be more effective than first-generation azoles in the prevention of fungal infections in hematology patients. We performed a systematic review with meta-analysis of randomized controlled trials comparing second- with first-generation azoles in hematology patients with respect to proven or ...
journal_title:Annals of hematology
pub_type: 杂志文章,meta分析,评审
doi:10.1007/s00277-013-1693-5
更新日期:2013-06-01 00:00:00
abstract::In follicular lymphoma the t(14;18) might be useful as a tumor marker in predicting the quality of the response to treatment. We investigated whether analyzing numbers of t(14;18)-positive cells in peripheral blood correlated with remission status in individual patients receiving a variety of treatments. Numbers of ci...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-003-0762-6
更新日期:2003-12-01 00:00:00
abstract::Many studies have confirmed that overexpressed WT1 exists in leukemic cells, especially in AML. However, the immunophenotypic features of this sort of leukemic cells remain to be unclarified. We retrospectively analyzed the immunophenotype of 283 newly diagnosed AML patients with intermediated and poor cytogenetic ris...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-019-03808-6
更新日期:2020-02-01 00:00:00
abstract::An additional affiliation for the first author was not indicated. Hyewon Lee is also affiliated with: Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, South Korea. ...
journal_title:Annals of hematology
pub_type: 杂志文章,已发布勘误
doi:10.1007/s00277-019-03868-8
更新日期:2020-01-01 00:00:00
abstract::Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment option for myelofibrosis (MF) despite the emergence of novel targeted therapies. To reduce graft rejection and graft-versus-host disease (GvHD), current allo-HCT protocols often include in vivo T lymphocyte depletion using pol...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究
doi:10.1007/s00277-016-2758-z
更新日期:2016-10-01 00:00:00
abstract::Methods to estimate bone marrow plasma cells (BMPC) basically include histopathology, cytomorphology, and flow cytometry. The present study compares the outcomes of these methods with special focus on the impact of BMPC-specific characteristics on their recovery by either method. Laboratory reports of diagnostic sampl...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究
doi:10.1007/s00277-020-04249-2
更新日期:2020-11-01 00:00:00
abstract::Since July 2017, different generic imatinib formulations have been introduced in Italy for the treatment of patients with chronic myeloid leukemia (CML). We analyzed 168 chronic phase CML patients treated with branded imatinib for a median of 12 years (range 1-16) at a single institution who switched to a single gener...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-020-04096-1
更新日期:2020-12-01 00:00:00
abstract::We discuss possible justifications to split study populations from a biometrical point of view. The existence of prognostic differences between subgroups are neither a sufficient nor a necessary reason to justify a splitting decision. There are essentially two separate types of relevant arguments to justify a split of...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/pl00022792
更新日期:2001-01-01 00:00:00
abstract::Azacitidine and decitabine, two hypomethylating agents, are known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who cannot endure intensive cytotoxic chemotherapy or are not eligible for transplantation. However, the treatment response rate is l...
journal_title:Annals of hematology
pub_type: 杂志文章,评审
doi:10.1007/s00277-018-3464-9
更新日期:2018-11-01 00:00:00
abstract::Wilms' tumor gene 1 (WT1) is gaining increasing attention as a therapeutic target molecule due to its common expression in acute leukemias and its involvement in cell proliferation. Here, we reported on WT1 messenger RNA expression levels at diagnosis in a series of 238 adult acute lymphoblastic leukemia (ALL) samples...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-009-0746-2
更新日期:2009-12-01 00:00:00